ID

26303

Descripción

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00706030

Link

https://clinicaltrials.gov/show/NCT00706030

Palabras clave

Versiones (1)
  1. 16/10/17 16/10/17 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

16 de octubre de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Cancer NCT00706030

Inglés

Eligibility Breast Cancer NCT00706030

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
confirmed pathologic diagnosis of a solid tumor that is not curable with available therapies for which hki-272 plus vinorelbine is a reasonable treatment option (part 1 only) or confirmed pathologic diagnosis of erbb-2-positive breast cancer (current stage iv) in female subjects for which vinorelbine plus hki-272 is a reasonable treatment option (part 2 only).
Descripción

Solid tumour incurable | HKI 272 Treatment option | Vinorelbine Treatment option | Breast Carcinoma HER2/Neu Positive TNM Breast tumor staging | Gender

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0280100
UMLS CUI [1,2]
C0175969
UMLS CUI [2,1]
C1454298
UMLS CUI [2,2]
C0683525
UMLS CUI [3,1]
C0078257
UMLS CUI [3,2]
C0683525
UMLS CUI [4,1]
C0678222
UMLS CUI [4,2]
C2348909
UMLS CUI [4,3]
C0474926
UMLS CUI [5]
C0079399
at least 1 prior antineoplastic chemotherapy treatment regimen for metastatic disease and at least 1 prior treatment with a trastuzumab-containing regimen for at least 6 weeks, for metastatic disease or subject relapsing under adjuvant treatment (part 2 only).
Descripción

Chemotherapy Regimen Quantity Neoplasm Metastasis | trastuzumab | Adjuvant therapy | Recurrent disease

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0027627
UMLS CUI [2]
C0728747
UMLS CUI [3]
C0677850
UMLS CUI [4]
C0277556
at least 1 measurable lesion as defined by response evaluation criteria in solid tumors (recist).
Descripción

Measurable lesion Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
more than 2 prior antineoplastic treatment regimens (excluding hormonotherapy) for metastatic disease. subjects who relapsed under adjuvant treatment shouldn't have received more than one line of chemotherapy for metastatic disease (part 2 only).
Descripción

Antineoplastic Therapy Quantity Neoplasm Metastasis | Exception Hormone Therapy | Adjuvant therapy | Recurrent disease | Chemotherapy Neoplasm Metastasis

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2346834
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0027627
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0279025
UMLS CUI [3]
C0677850
UMLS CUI [4]
C0277556
UMLS CUI [5,1]
C0392920
UMLS CUI [5,2]
C0027627
prior treatment with vinorelbine for metastatic setting, or prior treatment with any erbb-2 targeted agents except trastuzumab (part 2 only). up to 20 subjects with erbb-2-overexpressing metastatic breast cancer who have been previously exposed to lapatinib but are not refractory to lapatinib may be enrolled in part 2.
Descripción

Vinorelbine Neoplasm Metastasis | Pharmaceutical Preparations Targeting erbB-2 | Exception trastuzumab | Secondary malignant neoplasm of female breast erbB-2 Overexpression | lapatinib

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0078257
UMLS CUI [1,2]
C0027627
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1521840
UMLS CUI [2,3]
C0069515
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0728747
UMLS CUI [4,1]
C0346993
UMLS CUI [4,2]
C0069515
UMLS CUI [4,3]
C1514559
UMLS CUI [5]
C1506770
prior treatment with anthracyclines with a cumulative dose of doxorubicin of greater than 400 mg/m2, or of epirubicin dose of greater than 800 mg/m2, or the equivalent dose for other anthracyclines or derivatives (part 2 only).
Descripción

Anthracyclines | Doxorubicin Cumulative Dose | Epirubicin Dose | Anthracycline Derivatives Dose Equivalent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0282564
UMLS CUI [2,1]
C0013089
UMLS CUI [2,2]
C2986497
UMLS CUI [3,1]
C0014582
UMLS CUI [3,2]
C0178602
UMLS CUI [4,1]
C0282564
UMLS CUI [4,2]
C0243072
UMLS CUI [4,3]
C0178602
UMLS CUI [4,4]
C0205163
Volver a la parte superior de la página

Similar models

Eligibility Breast Cancer NCT00706030

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Solid tumour incurable | HKI 272 Treatment option | Vinorelbine Treatment option | Breast Carcinoma HER2/Neu Positive TNM Breast tumor staging | Gender
Item
confirmed pathologic diagnosis of a solid tumor that is not curable with available therapies for which hki-272 plus vinorelbine is a reasonable treatment option (part 1 only) or confirmed pathologic diagnosis of erbb-2-positive breast cancer (current stage iv) in female subjects for which vinorelbine plus hki-272 is a reasonable treatment option (part 2 only).
boolean
C0280100 (UMLS CUI [1,1])
C0175969 (UMLS CUI [1,2])
C1454298 (UMLS CUI [2,1])
C0683525 (UMLS CUI [2,2])
C0078257 (UMLS CUI [3,1])
C0683525 (UMLS CUI [3,2])
C0678222 (UMLS CUI [4,1])
C2348909 (UMLS CUI [4,2])
C0474926 (UMLS CUI [4,3])
C0079399 (UMLS CUI [5])
Chemotherapy Regimen Quantity Neoplasm Metastasis | trastuzumab | Adjuvant therapy | Recurrent disease
Item
at least 1 prior antineoplastic chemotherapy treatment regimen for metastatic disease and at least 1 prior treatment with a trastuzumab-containing regimen for at least 6 weeks, for metastatic disease or subject relapsing under adjuvant treatment (part 2 only).
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
C0728747 (UMLS CUI [2])
C0677850 (UMLS CUI [3])
C0277556 (UMLS CUI [4])
Measurable lesion Quantity
Item
at least 1 measurable lesion as defined by response evaluation criteria in solid tumors (recist).
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Antineoplastic Therapy Quantity Neoplasm Metastasis | Exception Hormone Therapy | Adjuvant therapy | Recurrent disease | Chemotherapy Neoplasm Metastasis
Item
more than 2 prior antineoplastic treatment regimens (excluding hormonotherapy) for metastatic disease. subjects who relapsed under adjuvant treatment shouldn't have received more than one line of chemotherapy for metastatic disease (part 2 only).
boolean
C2346834 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0279025 (UMLS CUI [2,2])
C0677850 (UMLS CUI [3])
C0277556 (UMLS CUI [4])
C0392920 (UMLS CUI [5,1])
C0027627 (UMLS CUI [5,2])
Vinorelbine Neoplasm Metastasis | Pharmaceutical Preparations Targeting erbB-2 | Exception trastuzumab | Secondary malignant neoplasm of female breast erbB-2 Overexpression | lapatinib
Item
prior treatment with vinorelbine for metastatic setting, or prior treatment with any erbb-2 targeted agents except trastuzumab (part 2 only). up to 20 subjects with erbb-2-overexpressing metastatic breast cancer who have been previously exposed to lapatinib but are not refractory to lapatinib may be enrolled in part 2.
boolean
C0078257 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C0069515 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0728747 (UMLS CUI [3,2])
C0346993 (UMLS CUI [4,1])
C0069515 (UMLS CUI [4,2])
C1514559 (UMLS CUI [4,3])
C1506770 (UMLS CUI [5])
Anthracyclines | Doxorubicin Cumulative Dose | Epirubicin Dose | Anthracycline Derivatives Dose Equivalent
Item
prior treatment with anthracyclines with a cumulative dose of doxorubicin of greater than 400 mg/m2, or of epirubicin dose of greater than 800 mg/m2, or the equivalent dose for other anthracyclines or derivatives (part 2 only).
boolean
C0282564 (UMLS CUI [1])
C0013089 (UMLS CUI [2,1])
C2986497 (UMLS CUI [2,2])
C0014582 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0282564 (UMLS CUI [4,1])
C0243072 (UMLS CUI [4,2])
C0178602 (UMLS CUI [4,3])
C0205163 (UMLS CUI [4,4])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial